TIDMPOLB
RNS Number : 9157Z
Poolbeg Pharma PLC
17 January 2024
Poolbeg Pharma plc
Further Data Confirms POLB 001's Potential in Cancer
Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Market opportunity estimated to be greater than US$1 billion
Key highlights
- Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model
- Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS
- Independent Advisory Board supportive of POLB 001's potential
to both prevent and treat cancer immunotherapy-induced CRS
- An Investor Meet Company presentation scheduled at 6pm on 17
January 2024 with Poolbeg management and Key Opinion Leader, Dr
Martin Kaiser
17 January 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, today announces
promising in vivo results for POLB 001 in addressing cancer
immunotherapy-induced CRS.
Positive study results
POLB 001 demonstrated efficacy in reducing cancer
immunotherapy-induced CRS in an in vivo animal model with CRS
symptoms significantly improved following administration of POLB
001. Reductions were seen in all serum proinflammatory cytokines
tested.
The results, together with the data from the recent LPS human
challenge tria l, further support the Company's strategic expansion
of the Phase II ready POLB 001 to treat and prevent cancer
immunotherapy-induced CRS. The data also strengthens and
facilitates the expansion of patent applications for POLB 001 in
cancer immunotherapy-induced CRS.
Market opportunity estimated at over US$1 billion
Largely due to the CRS risk (which can be life threatening),
administration of cancer immunotherapies, such as bispecific
antibodies, is currently restricted to specialist cancer centres
which limits uptake of these effective therapies. As an oral
therapy to prevent or treat CRS, POLB 001 has the potential to
enable broader use of cancer immunotherapies in an outpatient
setting. The Company believes that POLB 001 represents a
significant market opportunity estimated at > US$1 billion in
Multiple Myeloma, High Grade Lymphoma and Acute Lymphoblastic
Leukaemia alone. Cancer immunotherapies are being widely developed
across a broader range of haematological malignancies, solid
tumours and immune inflammatory diseases, which represents an even
greater market opportunity.
In the U.S., the American Cancer Society estimates that there
will be 24.6 million cases of cancer by 2030(1,2) . Cancer
immunotherapies, such as bispecific antibodies and CAR T cell
therapy, are rapidly moving into earlier lines of treatment in many
tumour types, with these markets anticipated to grow to US$100bn+
(35% CAGR) by 2030(3) .
Independent Advisory Board Supportive of POLB 001's
Potential
Poolbeg convened an Independent Advisory Board with
international Key Opinion Leaders, healthcare payers and clinical
trial experts, which endorsed t he attractiveness of POLB 001's
Target Product Profile (TPP) and its potential as an oral therapy
to address the significant unmet medical need of cancer
immunotherapy-induced CRS. POLB 001 has been shown to reduce
hyperinflammation without complete ablation of an effective immune
response, which makes it potentially a very attractive therapy for
this disease area.
Prof. Gareth Morgan, NYU Langone, United States said "Bispecific
antibodies will only be delivered in specialist cancer centres
until there is a way to make them safer. POLB 001 could make
treatment safe enough to extend bispecifics to a much wider patient
population".
Dr Martin Kaiser, Reader/Associate Professor in Molecular
Haematology at The Institute of Cancer Research and Haematology
Consultant at The Royal Marsden Hospital said, "Patients undergoing
cancer immunotherapy treatment that suffer with CRS can be
critically ill which, alongside a weakened immune system, can
further increase their risk of infection. Preventing CRS in the
first instance would have a significant impact on patient health
and wellbeing, as well as reducing the burden on the healthcare
system. Current CRS treatments require intravenous infusion, which
is difficult to deliver out of hospital, and some can only be used
off label in combination with bispecific antibodies. If there was a
therapy that was orally delivered, a whole lot of infrastructure
requirement falls away."
David Allmond, Chief Business Officer of Poolbeg Pharma,
commented: "POLB 001 has the potential to revolutionise the impact
of cancer immunotherapies by enabling safer and broader use in an
outpatient setting, reducing healthcare resource utilisation and
making these next generation cancer treatments more widely
available to the patients that need them. The pharmaceutical sector
is seeking an effective solution for CRS and, as an oral therapy,
we believe there is a significant opportunity for POLB 001 to meet
this critical unmet medical need and have a positive impact on
global health."
Investor presentation
Poolbeg's management team along with Martin Kaiser,
Reader/Associate Professor in Molecular Haematology at The
Institute of Cancer Research and Haematology Consultant at The
Royal Marsden Hospital, will provide a live presentation via the
Investor Meet Company platform on Wednesday 17 January 2024 at 6pm
GMT.
The presentation is open to analysts and investors, those who
already follow Poolbeg on the Investor Meet Company platform will
automatically be invited. Investors can sign up to Investor Meet
for free and add Poolbeg Pharma plc to their company dashboard via:
https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
References
1. The American Cancer Society (ACS)
2. The International Agency for Research on Cancer (IARC)
3. CAR T Cell Therapy Market Analysis 2023-2030; Bispecific
Antibodies Market Size, Share & Trends Analysis Report, Grand
View Research
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Vici Rabbetts, Elena poolbeg@optimumcomms.com
Bates
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team has been
strengthened by the appointment of three former members of the
Amryt Pharma plc leadership team, with the intention of repeating
Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
including CRS induced by cancer immunotherapies, infectious
disease, and metabolic conditions such as obesity with the
development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials
to identify clinically relevant drug targets and treatments,
leading to faster development and greater commercial appeal.
Forward-Looking Statements
This announcement may contain forward-looking statements and the
words "expect", "anticipate", "intends", "plan", "estimate", "aim",
"forecast", "project" and similar expressions (or their negative)
identify certain of these forward-looking statements. The
forward-looking statements in this announcement are based on
numerous assumptions and Poolbeg's present and future business
strategies and the environment in which Poolbeg expects to operate
in the future. Forward-looking statements involve inherent known
and unknown risks, uncertainties and contingencies because they
relate to events and depend on circumstances that may or may not
occur in the future and may cause the actual results, performance
or achievements to be materially different from those expressed or
implied by such forward-looking statements. These statements are
not guarantees of future performance or the ability to identify and
consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or
estimate precisely, such as future market conditions, currency
fluctuations, the behaviour of other market participants, the
outcome of clinical trials, the actions of regulators and other
factors such as Poolbeg's ability to obtain financing, changes in
the political, social and regulatory framework in which Poolbeg
operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication
or guarantee of future results, and no representation or warranty,
express or implied, is made regarding future performance. No person
is under any obligation to update or keep current the information
contained in this announcement or to provide the recipient of it
with access to any additional relevant information.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUPCGUPCPGQ
(END) Dow Jones Newswires
January 17, 2024 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
